Preparation and/or formulation of proteins cross-linked with polysaccharides
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jul 20, 2021
Grant Date -
Aug 6, 2020
app pub date -
Apr 23, 2020
filing date -
Nov 23, 2010
priority date (Note) -
In Force
status (Latency Note)
![]() |
A preliminary load of PAIR data current through [] has been loaded. Any more recent PAIR data will be loaded within twenty-four hours. |
PAIR data current through []
A preliminary load of cached data will be loaded soon.
Any more recent PAIR data will be loaded within twenty-four hours.
![]() |
Next PAIR Update Scheduled on [ ] |

Importance

US Family Size
|
Non-US Coverage
|
Abstract
Therapeutic compositions and/or formulations are provided, comprising: at least one cross-linked protein matrix, wherein the at least one cross-linked protein matrix comprises at least one protein residue and at least one saccharide-containing residue, and methods of producing the same. The cross-linked protein matrix may be derived from cross-linking a full length or substantially full length protein, such as tropoelastin, elastin, albumin, collagen, collagen monomers, immunoglobulins, insulin, and/or derivatives or combinations thereof, with a saccharide containing cross-linking agent, such as a polysaccharide cross-linking agent derived from, for example, hyaluronic acid or a cellulose derivative. The therapeutic compositions may be administered topically or by injection. The present disclosure also provides methods, systems, and/or kits for the preparation and/or formulation of the compositions disclosed herein.
First Claim
all claims..Other Claims data not available
Family

- 15 United States
- 10 France
- 8 Japan
- 7 China
- 5 Korea
- 2 Other
Patent Owner(s)
Patent Owner | Address | |
---|---|---|
ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED | CLONSHAUGH INDUSTRIAL ESTATE COOLOCK DUBLIN 17 |
International Classification(s)
- A61K:PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOS....
- C08H:DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
- C08B:POLYSACCHARIDES; DERIVATIVES THEREOF
- A61Q:USE OF COSMETICS OR SIMILAR TOILET PREPARATIONS
- A61L:METHODS OR APPARATUS FOR STERILISING MATERIALS OR ....
- C08L:COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C07K:PEPTIDES

- 2020 Application Filing Year
- A61K Class
- 21530 Applications Filed
- 7999 Patents Issued To-Date
- 37.16 % Issued To-Date
Inventor(s)
Inventor Name | Address | # of filed Patents | Total Citations |
---|---|---|---|
Sommer-Knudsen, Jens | Gordon, AU | 12 | 301 |
# of filed Patents : 12 Total Citations : 301 |
Cited Art Landscape
- No Cited Art to Display

Patent Citation Ranking
- 0 Citation Count
- A61K Class
- 0 % this patent is cited more than
- 4 Age
Forward Cite Landscape
- No Forward Cites to Display

Maintenance Fees
Fee | Large entity fee | small entity fee | micro entity fee | due date |
---|---|---|---|---|
3.5 Year Payment | $1600.00 | $800.00 | $400.00 | Jan 20, 2025 |
7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Jan 20, 2029 |
11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Jan 20, 2033 |
Fee | Large entity fee | small entity fee | micro entity fee |
---|---|---|---|
Surcharge - 3.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
Surcharge - 7.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
Surcharge - 11.5 year - Late payment within 6 months | $160.00 | $80.00 | $40.00 |
Surcharge after expiration - Late payment is unavoidable | $700.00 | $350.00 | $175.00 |
Surcharge after expiration - Late payment is unintentional | $1,640.00 | $820.00 | $410.00 |
Full Text

Legal Events
- No Legal Status data available.

Matter Detail

Renewals Detail
